Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | APP | P05067 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7164883 | 0.90 | BACE1 (0.56) | MAPTL3MBTL1KDM4EBACE1HDAC1 | |
| SCHEMBL12263035 | 0.86 | MAPT (0.64) | MAPTL3MBTL1APPKDM4EGAA | |
| SCHEMBL132544 | 0.85 | MAPT (0.42) | MAPTL3MBTL1APPKDM4EBACE1 | |
| SCHEMBL29922357 | 0.84 | BACE1 (0.65) | MAPTAPPKDM4EBACE1HDAC1 | |
| SCHEMBL396451 | 0.84 | BACE1 (0.65) | MAPTAPPKDM4EBACE1HDAC1 | |
| SCHEMBL10353242 | 0.84 | ACLY (0.48) | MAPTL3MBTL1APPKDM4EBACE1 | |
| SCHEMBL95028 | 0.82 | HDAC1 (0.46) | MAPTL3MBTL1APPKDM4EHDAC1 | |
| SCHEMBL11019341 | 0.81 | MAPT (0.55) | MAPTL3MBTL1APPKDM4EBACE1 | |
| SCHEMBL9683129 | 0.81 | MAPT (0.47) | MAPTL3MBTL1APPKDM4EMEN1 | |
| SCHEMBL9134263 | 0.81 | HDAC1 (0.49) | MAPTAPPKDM4EBACE1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200377505-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-12-03 | — | — | US | disclosed |
| CN-105218537-B | Berberine benzimidazole compounds or pharmaceutically acceptable salts thereof as well as preparation methods and applications of berberine benzimidazole compounds or pharmaceutically acceptable salts of berberine benzimidazole compounds | 西南大学 | 2017-01-11 | — | — | CN | disclosed |
| US-8975247-B2 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNION UNIVERSITY (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975247-B2 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNION UNIVERSITY (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-01 | — | — | US | disclosed |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-01 | — | — | US | disclosed |
| US-20120058085-A1 | Deuterium Modified Benzimidazoles | CONCERT PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20120058085-A1 | Deuterium Modified Benzimidazoles | CONCERT PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| WO-2010132810-A1 | DEUTERIUM MODIFIED BENZIMIDAZOLES | CONCERT PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100284970-A1 | BENZIMIDAZOLE MODULATORS OF H1 RECEPTOR AND/OR NS4B PROTEIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100284970-A1 | BENZIMIDAZOLE MODULATORS OF H1 RECEPTOR AND/OR NS4B PROTEIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100284970-A1 | BENZIMIDAZOLE MODULATORS OF H1 RECEPTOR AND/OR NS4B PROTEIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010118286-A2 | BENZIMIDAZOLE MODULATORS OF H1 RECEPTOR AND/OR NS4B PROTEIN ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010107739-A2 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058085-A1 | Deuterium Modified Benzimidazoles | POLRMT, EIF2AK2, DUT | MAPT 4232/4885L3MBTL1 2089/4885APP 4350/4885 |
| US-20200377505-A1 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | AZI2, ATP6V1B1, GLS | MAPT 4542/4885L3MBTL1 4462/4885APP 4883/4885 |
| US-20100284970-A1 | BENZIMIDAZOLE MODULATORS OF H1 RECEPTOR AND/OR NS4B PROTEIN | HRH4, H1-4, HRH3 | MAPT 3023/4885L3MBTL1 3783/4885APP 4127/4885 |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NSUN3, RNGTT, NSUN2 | MAPT 4638/4885L3MBTL1 183/4885APP 4794/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | MAPT 4569/4885L3MBTL1 389/4885APP 4550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.